$TDAC

Translational Development Acquisition Corp.

No enriched coverage for $TDAC in the last 7 days.

No SEC Form 4 filings for $TDAC in the last 30 days.

See all $TDAC insider activity →
Med

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

Translational Development Acquisition Corp. (TDAC): Entry into a Material Definitive Agreement

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2621361d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Certain information marked with [***] has been excluded from this exhibit because it is not material and is the type that the registrant treats as private or confidential. SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMEN

TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger

Translational Development Acquisition Company (NYSE: TDAC) said ProLogium filed an initial Form F-4 with the SEC as part of the de-SPAC merger announced May 27, 2026. TDAC said the filing provides more history and transaction details for investors, noting it remains subject to SEC review and possible revisions.

TDAC sentiment & insider activity

Recent TDAC coverage spans corporate actions and mergers & acquisitions.

What's driving TDAC

  • Financing commitment reduces deal funding risk for TDAC’s SPAC transaction, supporting probability of closing.

    finanznachrichten.de · Jul 28, 2026

  • The 8-K adds deal financing mechanics via a subscription agreement, supporting deal progression but without disclosed economics in the excerpt.

    SEC EDGAR 8-K · Jul 27, 2026

  • The fresh F-4 filing is a procedural but concrete step that can reduce deal uncertainty and keep merger timelines in focus.

    prnewswire.com · Jul 6, 2026

  • Shareholder-approved extension reduces liquidation risk and preserves time to complete a business combination; near-term trading may hinge on extension mechanics and any implied runway.

    SEC EDGAR 8-K · Jun 18, 2026

  • Sponsor-to-public share conversion increases Class A outstanding without cash proceeds and reiterates transfer/redemption restrictions.

    SEC EDGAR 8-K · Jun 12, 2026

AlphAI scores every news story that mentions TDAC with an AI model for sentiment and relevance, and aggregates insider trades from Translational Development Acquisition Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TDAC

Score
$TDACMedAI 8/10

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

$TDACMed

Translational Development Acquisition Corp. (TDAC): Entry into a Material Definitive Agreement

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2621361d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Certain information marked with [***] has been excluded from this exhibit because it is not material and is the type that the registrant treats as private or confidential. SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMEN

$TDACMed

Translational Development Acquisition Corp. (TDAC): Entry into a Material Definitive Agreement

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false --12-31 0001926599 00-0000000 0001926599 2026-06-17 2026-06-17 0001926599 TDACU:UnitsEachConsistingOfOneClassaOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2026-06-17 2026-06-17 0001926599 TDACU:ClassaOrdinaryShares0.0001ParValuePerShareMember 2026-06-17

$TDACLow

Translational Development Acquisition Corp. (TDAC): Unregistered Sales of Equity Securities

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001926599 00-0000000 0001926599 2026-06-12 2026-06-12 0001926599 TDACU:UnitsEachConsistingOfOneClassaOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2026-06-12 2026-06-12 0001926599 TDACU:ClassaOrdinaryShares0.0001ParValuePerShareMember 2026-06-12 2026-06

Related tickers